When using Liraglutide tablets to treat amyotrophic lateral sclerosis, attention should be paid to the three major risks of liver toxicity, neutropenia, and drug interactions. Specific precautions are as follows.

1、 Hepatotoxicity monitoring

1. Pre treatment examination

Before starting to take Liraglutide tablets, a liver function test, including serum transaminase and other indicators, should be performed as a baseline reference. Individuals with a history of liver dysfunction should be evaluated with caution.

2. Regular monitoring during treatment

During the medication period, regular liver function check ups should be conducted, usually once a month for the first three months, followed by regular check ups thereafter. If there is an increase in transaminase levels, the monitoring frequency needs to be increased.

3. Be alert to symptoms of liver injury

If symptoms such as worsening fatigue, decreased appetite, nausea, vomiting, abdominal pain, jaundice (yellowing of skin or eye whites), and darkened urine color occur, the doctor should be informed immediately and liver function should be rechecked.

4. Handling exceptions

If there is a significant increase in transaminase levels or liver damage symptoms, medication should be reduced or stopped under the guidance of a doctor, and should not be continued on its own. Patients with severe liver damage should permanently discontinue medication.

2、 Neutropenia

1. Pre treatment examination

Before starting medication, a blood routine should be checked to understand the baseline level of neutrophil count. Individuals with a history of hematological disorders should exercise caution.

2. Monitoring during treatment

During medication, regular blood routine checks should be conducted, with particular attention paid to neutrophil count. If there is unexplained fever, sore throat, oral ulcers or infection symptoms, medical examination should be sought in a timely manner.

3. Be alert to the risk of infection

Neutropenia increases the risk of infection. During medication, personal hygiene should be taken into account to avoid contact with the source of infection. If there are signs of infection such as fever, medical attention should be sought immediately.

4. Handling exceptions

If the neutrophil count significantly decreases, the dosage should be adjusted or discontinued under the guidance of a doctor, and blood tests should be closely monitored for changes.

3、 Drug interactions

1. Drugs metabolized by CYP1A2

Liraglutide tablets are mainly metabolized by CYP1A2 enzyme. When drugs that are metabolized by the same enzyme as caffeine, theophylline, and chlorpromazine are used in combination, they may affect each other's blood drug concentrations and should be used with caution.

2. Drugs that inhibit CYP1A2

When used in combination with CYP1A2 inhibitors such as fluvoxamine and ciprofloxacin, it may increase the blood concentration of liraglutide and increase the risk of adverse reactions. The dosage should be avoided or adjusted.

3. Drugs that induce CYP1A2

When used in combination with CYP1A2 inducers such as rifampicin and omeprazole, the efficacy of liraglutide may be reduced, and it is necessary to monitor the efficacy and adjust the regimen.

4. Other precautions

During medication, alcohol consumption should be avoided as it may increase the burden on the liver. Before using any new drugs (including prescription drugs, over-the-counter drugs, and herbal medicines), doctors should be informed to assess the risk of interactions.